Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

Kei Nakashima, Masayuki Ishida, Hiroyuki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku, Yuko Nitahara, Yasutoshi Kido, Yoshio Hirota
doi: https://doi.org/10.1101/2022.06.23.22276536

Article usage

Article usage: June 2022 to November 2024

AbstractFullPdf
Jun 202294021100
Jul 2022325481
Aug 202286314
Sep 20228356
Oct 202278113
Nov 20225717
Dec 202266215
Jan 202349113
Feb 202330217
Mar 20232302
Apr 20234317
May 202320115
Jun 20231044
Jul 20231519
Aug 2023211112
Sep 20231246
Oct 20231446
Nov 20232184
Dec 20231211
Jan 2024903
Feb 20241507
Mar 20241256
Apr 20241518
May 2024735
Jun 202411111
Jul 20246525
Aug 202412314
Sep 20242019
Oct 20246010
Nov 2024706
Back to top
Posted June 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
Kei Nakashima, Masayuki Ishida, Hiroyuki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku, Yuko Nitahara, Yasutoshi Kido, Yoshio Hirota
medRxiv 2022.06.23.22276536; doi: https://doi.org/10.1101/2022.06.23.22276536
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area